IGF2BP1 and colorectal carcinoma: There is a bulk of evidence accumulated indicating that IGF2BP1 sustains MYC expression in tumor cells derived from various cancers in vitro (e.g.: mammary carcinomas [66]; ovarian carcinomas [13]; colorectal carcinomas [57]).